Cambridge innovator backed by US health powerhouse

Cambridge innovator backed by US health powerhouse

2021-02-15

The award is designed to efficiently explore neuromodulation parameters to help accelerate the development of neural treatments for chronic disease, using BIOS’ unique neural biomarker technology.

At the end of 2020, BIOS launched its pioneering Autonomic Therapy Initiative (BIOS ATI), which will see the company work with world-leading partners to deliver a new class of treatments for heart disease using AI-powered neural interfaces. 

The primary focus of the SPARC program is to catalyse the bioelectronic medicine field by providing a scientific and technological foundation for future neuromodulation devices and protocols to improve organ function.